Coronary artery vasospasm refers to the constriction of coronary arteries, potentially leading to complete or nearly complete vessel occlusion. In 1959, Dr. Myron Prinzmetal introduced a distinct form of angina, differing from the classic Heberden angina initially outlined in 1772.
This vasospastic condition has the potential to induce acute ischemia, manifesting across the entire spectrum of angina, ranging from stable angina to acute coronary syndrome.
The exact cause of coronary artery vasospasm is not always clear, but it is often associated with an imbalance in the regulation of smooth muscle tone in the arterial walls. Factors such as endothelial dysfunction, increased sensitivity to vasoconstrictors, and abnormal nerve function may contribute.
Epidemiology
The prevalence of CAVS is most pronounced between the ages of 40 and 70, diminishing after that. The global distribution reveals varying incidence rates, with the Japanese population exhibiting a higher prevalence compared to Western populations.
Additionally, provocative testing indicates a greater frequency of multiple spasms in the Japanese population compared to Caucasians. A German study uncovered that among patients with suspected obstructive coronary artery disease, every fourth patient lacked a culprit lesion. Notably, half of these patients tested with acetylcholine were confirmed to have CAVS.
Anatomy
Pathophysiology
The pathophysiology is complex and involves multifactorial mechanisms. One primary contributor is the abnormal reactivity of vascular smooth muscle cells within the coronary arteries. Endothelial dysfunction, where the inner lining of the blood vessels fails to produce sufficient vasodilatory factors, plays a pivotal role. This dysfunction leads to an imbalance between vasoconstrictors and vasodilators.
One of the critical vasoconstrictors implicated in CAVS is the increased activity of the sympathetic nervous system, resulting in heightened release of catecholamines such as norepinephrine. These catecholamines act on alpha-adrenergic receptors in the coronary arteries, triggering vasoconstriction. Additionally, abnormalities in calcium homeostasis contribute to the pathophysiology, with an increased influx of calcium ions into vascular smooth muscle cells promoting excessive contraction.
Endothelin-1, a potent vasoconstrictor released by the endothelium, further exacerbates the constriction of coronary arteries in CAVS. Conversely, impaired release of nitric oxide, a crucial vasodilator, further tilts the balance towards vasoconstriction. Oxidative stress and inflammation also play roles in perpetuating endothelial dysfunction and vascular reactivity.
The episodes of vasospasm in CAVS are often unpredictable and can occur at rest, particularly during periods of heightened sympathetic activity, such as the early morning hours. These spasms result in a temporary reduction of blood flow to the myocardium, leading to angina-like symptoms.
Etiology
Genetic Predisposition: There is evidence to suggest a genetic component in CAVS. Some individuals may inherit a predisposition that makes them more susceptible to abnormal vascular responses, leading to vasospasms.
Smooth Muscle Abnormalities: Dysfunction in the smooth muscle cells of the coronary arteries can contribute to vasospasm. Abnormal regulation of these cells may result in inappropriate and excessive constriction.
Endothelial Dysfunction: Dysfunction in the endothelial cells can disrupt the balance between vasodilation and vasoconstriction, contributing to vasospasm.
Autonomic Nervous System Imbalance: An imbalance in the autonomic nervous system, particularly between the sympathetic and parasympathetic branches, can influence the regulation of coronary artery tone. This imbalance may contribute to vasospasm.
Vasoactive Substances: Abnormal levels of vasoactive substances, such as endothelin and serotonin, can induce coronary artery constriction. Imbalances in these substances may play a role in the development of vasospasm.
Environmental Triggers: Various external factors can act as triggers for vasospasm. These may include exposure to cold temperatures, emotional stress, certain medications, or substances that affect vascular tone.
Genetics
Prognostic Factors
Recurring instances of angina are commonly observed in 4% to 19% of patients. Factors such as advanced age and compromised left ventricular function have been recognized as contributors to an unfavorable prognosis in individuals presenting with acute coronary syndrome attributed to coronary artery vasospasm.
Clinical History
Approximately 20% to 30% of individuals reporting chest pain and undergoing assessment for obstructive coronary artery disease through coronary angiography exhibit normal coronary arteries. These patients may or may not exhibit symptoms, and if symptomatic, they might experience typical anginal complaints during episodes of vasospasm.
Pain induced by coronary artery vasospasm can manifest at rest, notably between the night and early morning, often accompanied by reduced exercise tolerance, particularly in the morning hours.
The pain associated with CAVS can be characterized as crushing and substernal, featuring radiation to the jaw or arm. Patients may describe the discomfort as intense, with notable relief observed upon the administration of sublingual nitroglycerin.
It is crucial to recognize that the symptoms may vary, and the presence of vasospasm-induced pain can significantly impact a patient’s quality of life, affecting both daily activities and sleep patterns. These manifestations underscore the importance of a comprehensive understanding of CAVS-related symptoms to facilitate accurate diagnosis and targeted management strategies.
Physical Examination
Conducting a comprehensive physical examination is imperative, particularly focusing on the cardiovascular system. The examination should commence by recording vital signs to assess and ensure hemodynamic stability. Subsequently, auscultation of the heart sounds becomes paramount.
Careful attention should be dedicated to evaluating the rhythm, rate, presence of murmurs, and any additional heart sounds like S3 or S4. Moreover, a thorough pulmonary examination is integral, with a specific emphasis on detecting the emergence of crackles.
The presence of crackles may serve as a crucial indicator, potentially suggesting the onset of pulmonary edema. This comprehensive evaluation allows healthcare providers to gather essential information about the cardiovascular status of the patient, facilitating a more accurate diagnosis and informing appropriate management strategies.
The foundation for treating and managing this patient population lies in medical therapy coupled with risk factor modification. Initial treatment involves the administration of nitrates or calcium channel blockers. Nitrates induce the relaxation of vascular muscle by activating guanylate cyclase, leading to an increase in the production of cGMP.
In addressing coronary artery vasospasm (CAVS), it is also essential to employ calcium channel blockers that reduce calcium intake into the vascular smooth muscle. Often, a combination of calcium channel blockers and nitrates may be employed to achieve a more comprehensive vasodilatory effect and better control of vasospastic episodes. This dual approach helps address the underlying vascular smooth muscle dysfunction and provides effective relief from the symptoms associated with CAVS.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
While vasodilatation is generally effective in alleviating coronary artery vasospasm, approximately 20% of patients exhibit resistance to drug therapy, even with long-acting medications. Percutaneous balloon angioplasty, in such cases, has not yielded favorable results. Although percutaneous coronary intervention has been explored alongside continued medication use for long-term management, some patients experience recurrent vasospasm in different locations.
Consequently, the consideration of coronary stenting coupled with long-term medical therapy is warranted only for patients exhibiting significant stenosis resulting from CAVS. The utilization of implantable cardioverter-defibrillators (ICDs) in CAVS patients presenting with ventricular tachycardia or ventricular fibrillation remains uncertain. However, there have been reported instances of positive outcomes when implanting ICDs in patients who survive fatal ventricular arrhythmias associated with CAVS.
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Administration of a pharmaceutical agent
Calcium Channel blockersÂ
Calcium channel blockers reduce the entry of calcium into vascular smooth muscle cells. By inhibiting calcium influx, these medications prevent the excessive contraction of smooth muscle in the blood vessels, helping to alleviate vasospasm.
Diltiazem is commonly used to prevent and manage coronary artery vasospasm. By reducing calcium entry into smooth muscle cells, it helps prevent excessive vasoconstriction and promotes vasodilation in coronary arteries. Â
NitratesÂ
Nitrates work by releasing nitric oxide, which activates guanylate cyclase, leading to increased production of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels result in vasodilation and relaxation of vascular smooth muscle. Nitroglycerin is often used to provide rapid relief during acute episodes of coronary artery vasospasm. By inducing vasodilation in coronary arteries, it helps alleviate spastic contractions and improve blood flow to the heart.Â
Various alternative therapies have been investigated for the treatment of Coronary Artery Vasospasm (CAVS). These include nicorandil (a nitrate and potassium channel activator), statins, magnesium, fasudil (a rho kinase inhibitor), aspirin, vitamins E and C, iloprost, selective serotonin receptor inhibitors, alpha-receptor blockade, and selective thromboxane A2 synthetase inhibition.
Despite some reported success with these alternatives, their effectiveness remains variable and limited, necessitating further comprehensive studies before they can be universally accepted as primary treatment options, akin to nitrates and calcium channel blockers.
It is crucial to exercise caution with beta-blockers in CAVS management, as they may potentially exacerbate vasospastic angina and are generally advised against in this context. Ongoing research is essential to establish the efficacy and safety profiles of these alternative therapies in the broader spectrum of CAVS treatment.Â
Coronary artery vasospasm refers to the constriction of coronary arteries, potentially leading to complete or nearly complete vessel occlusion. In 1959, Dr. Myron Prinzmetal introduced a distinct form of angina, differing from the classic Heberden angina initially outlined in 1772.
This vasospastic condition has the potential to induce acute ischemia, manifesting across the entire spectrum of angina, ranging from stable angina to acute coronary syndrome.
The exact cause of coronary artery vasospasm is not always clear, but it is often associated with an imbalance in the regulation of smooth muscle tone in the arterial walls. Factors such as endothelial dysfunction, increased sensitivity to vasoconstrictors, and abnormal nerve function may contribute.
The prevalence of CAVS is most pronounced between the ages of 40 and 70, diminishing after that. The global distribution reveals varying incidence rates, with the Japanese population exhibiting a higher prevalence compared to Western populations.
Additionally, provocative testing indicates a greater frequency of multiple spasms in the Japanese population compared to Caucasians. A German study uncovered that among patients with suspected obstructive coronary artery disease, every fourth patient lacked a culprit lesion. Notably, half of these patients tested with acetylcholine were confirmed to have CAVS.
The pathophysiology is complex and involves multifactorial mechanisms. One primary contributor is the abnormal reactivity of vascular smooth muscle cells within the coronary arteries. Endothelial dysfunction, where the inner lining of the blood vessels fails to produce sufficient vasodilatory factors, plays a pivotal role. This dysfunction leads to an imbalance between vasoconstrictors and vasodilators.
One of the critical vasoconstrictors implicated in CAVS is the increased activity of the sympathetic nervous system, resulting in heightened release of catecholamines such as norepinephrine. These catecholamines act on alpha-adrenergic receptors in the coronary arteries, triggering vasoconstriction. Additionally, abnormalities in calcium homeostasis contribute to the pathophysiology, with an increased influx of calcium ions into vascular smooth muscle cells promoting excessive contraction.
Endothelin-1, a potent vasoconstrictor released by the endothelium, further exacerbates the constriction of coronary arteries in CAVS. Conversely, impaired release of nitric oxide, a crucial vasodilator, further tilts the balance towards vasoconstriction. Oxidative stress and inflammation also play roles in perpetuating endothelial dysfunction and vascular reactivity.
The episodes of vasospasm in CAVS are often unpredictable and can occur at rest, particularly during periods of heightened sympathetic activity, such as the early morning hours. These spasms result in a temporary reduction of blood flow to the myocardium, leading to angina-like symptoms.
Genetic Predisposition: There is evidence to suggest a genetic component in CAVS. Some individuals may inherit a predisposition that makes them more susceptible to abnormal vascular responses, leading to vasospasms.
Smooth Muscle Abnormalities: Dysfunction in the smooth muscle cells of the coronary arteries can contribute to vasospasm. Abnormal regulation of these cells may result in inappropriate and excessive constriction.
Endothelial Dysfunction: Dysfunction in the endothelial cells can disrupt the balance between vasodilation and vasoconstriction, contributing to vasospasm.
Autonomic Nervous System Imbalance: An imbalance in the autonomic nervous system, particularly between the sympathetic and parasympathetic branches, can influence the regulation of coronary artery tone. This imbalance may contribute to vasospasm.
Vasoactive Substances: Abnormal levels of vasoactive substances, such as endothelin and serotonin, can induce coronary artery constriction. Imbalances in these substances may play a role in the development of vasospasm.
Environmental Triggers: Various external factors can act as triggers for vasospasm. These may include exposure to cold temperatures, emotional stress, certain medications, or substances that affect vascular tone.
Recurring instances of angina are commonly observed in 4% to 19% of patients. Factors such as advanced age and compromised left ventricular function have been recognized as contributors to an unfavorable prognosis in individuals presenting with acute coronary syndrome attributed to coronary artery vasospasm.
Approximately 20% to 30% of individuals reporting chest pain and undergoing assessment for obstructive coronary artery disease through coronary angiography exhibit normal coronary arteries. These patients may or may not exhibit symptoms, and if symptomatic, they might experience typical anginal complaints during episodes of vasospasm.
Pain induced by coronary artery vasospasm can manifest at rest, notably between the night and early morning, often accompanied by reduced exercise tolerance, particularly in the morning hours.
The pain associated with CAVS can be characterized as crushing and substernal, featuring radiation to the jaw or arm. Patients may describe the discomfort as intense, with notable relief observed upon the administration of sublingual nitroglycerin.
It is crucial to recognize that the symptoms may vary, and the presence of vasospasm-induced pain can significantly impact a patient’s quality of life, affecting both daily activities and sleep patterns. These manifestations underscore the importance of a comprehensive understanding of CAVS-related symptoms to facilitate accurate diagnosis and targeted management strategies.
Conducting a comprehensive physical examination is imperative, particularly focusing on the cardiovascular system. The examination should commence by recording vital signs to assess and ensure hemodynamic stability. Subsequently, auscultation of the heart sounds becomes paramount.
Careful attention should be dedicated to evaluating the rhythm, rate, presence of murmurs, and any additional heart sounds like S3 or S4. Moreover, a thorough pulmonary examination is integral, with a specific emphasis on detecting the emergence of crackles.
The presence of crackles may serve as a crucial indicator, potentially suggesting the onset of pulmonary edema. This comprehensive evaluation allows healthcare providers to gather essential information about the cardiovascular status of the patient, facilitating a more accurate diagnosis and informing appropriate management strategies.
The foundation for treating and managing this patient population lies in medical therapy coupled with risk factor modification. Initial treatment involves the administration of nitrates or calcium channel blockers. Nitrates induce the relaxation of vascular muscle by activating guanylate cyclase, leading to an increase in the production of cGMP.
In addressing coronary artery vasospasm (CAVS), it is also essential to employ calcium channel blockers that reduce calcium intake into the vascular smooth muscle. Often, a combination of calcium channel blockers and nitrates may be employed to achieve a more comprehensive vasodilatory effect and better control of vasospastic episodes. This dual approach helps address the underlying vascular smooth muscle dysfunction and provides effective relief from the symptoms associated with CAVS.
While vasodilatation is generally effective in alleviating coronary artery vasospasm, approximately 20% of patients exhibit resistance to drug therapy, even with long-acting medications. Percutaneous balloon angioplasty, in such cases, has not yielded favorable results. Although percutaneous coronary intervention has been explored alongside continued medication use for long-term management, some patients experience recurrent vasospasm in different locations.
Consequently, the consideration of coronary stenting coupled with long-term medical therapy is warranted only for patients exhibiting significant stenosis resulting from CAVS. The utilization of implantable cardioverter-defibrillators (ICDs) in CAVS patients presenting with ventricular tachycardia or ventricular fibrillation remains uncertain. However, there have been reported instances of positive outcomes when implanting ICDs in patients who survive fatal ventricular arrhythmias associated with CAVS.
Calcium Channel blockersÂ
Calcium channel blockers reduce the entry of calcium into vascular smooth muscle cells. By inhibiting calcium influx, these medications prevent the excessive contraction of smooth muscle in the blood vessels, helping to alleviate vasospasm.
Diltiazem is commonly used to prevent and manage coronary artery vasospasm. By reducing calcium entry into smooth muscle cells, it helps prevent excessive vasoconstriction and promotes vasodilation in coronary arteries. Â
NitratesÂ
Nitrates work by releasing nitric oxide, which activates guanylate cyclase, leading to increased production of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels result in vasodilation and relaxation of vascular smooth muscle. Nitroglycerin is often used to provide rapid relief during acute episodes of coronary artery vasospasm. By inducing vasodilation in coronary arteries, it helps alleviate spastic contractions and improve blood flow to the heart.Â
Various alternative therapies have been investigated for the treatment of Coronary Artery Vasospasm (CAVS). These include nicorandil (a nitrate and potassium channel activator), statins, magnesium, fasudil (a rho kinase inhibitor), aspirin, vitamins E and C, iloprost, selective serotonin receptor inhibitors, alpha-receptor blockade, and selective thromboxane A2 synthetase inhibition.
Despite some reported success with these alternatives, their effectiveness remains variable and limited, necessitating further comprehensive studies before they can be universally accepted as primary treatment options, akin to nitrates and calcium channel blockers.
It is crucial to exercise caution with beta-blockers in CAVS management, as they may potentially exacerbate vasospastic angina and are generally advised against in this context. Ongoing research is essential to establish the efficacy and safety profiles of these alternative therapies in the broader spectrum of CAVS treatment.Â
Â
medtigo
Coronary artery vasospasm
Updated :
July 2, 2024
Coronary artery vasospasm refers to the constriction of coronary arteries, potentially leading to complete or nearly complete vessel occlusion. In 1959, Dr. Myron Prinzmetal introduced a distinct form of angina, differing from the classic Heberden angina initially outlined in 1772.
This vasospastic condition has the potential to induce acute ischemia, manifesting across the entire spectrum of angina, ranging from stable angina to acute coronary syndrome.
The exact cause of coronary artery vasospasm is not always clear, but it is often associated with an imbalance in the regulation of smooth muscle tone in the arterial walls. Factors such as endothelial dysfunction, increased sensitivity to vasoconstrictors, and abnormal nerve function may contribute.
The prevalence of CAVS is most pronounced between the ages of 40 and 70, diminishing after that. The global distribution reveals varying incidence rates, with the Japanese population exhibiting a higher prevalence compared to Western populations.
Additionally, provocative testing indicates a greater frequency of multiple spasms in the Japanese population compared to Caucasians. A German study uncovered that among patients with suspected obstructive coronary artery disease, every fourth patient lacked a culprit lesion. Notably, half of these patients tested with acetylcholine were confirmed to have CAVS.
The pathophysiology is complex and involves multifactorial mechanisms. One primary contributor is the abnormal reactivity of vascular smooth muscle cells within the coronary arteries. Endothelial dysfunction, where the inner lining of the blood vessels fails to produce sufficient vasodilatory factors, plays a pivotal role. This dysfunction leads to an imbalance between vasoconstrictors and vasodilators.
One of the critical vasoconstrictors implicated in CAVS is the increased activity of the sympathetic nervous system, resulting in heightened release of catecholamines such as norepinephrine. These catecholamines act on alpha-adrenergic receptors in the coronary arteries, triggering vasoconstriction. Additionally, abnormalities in calcium homeostasis contribute to the pathophysiology, with an increased influx of calcium ions into vascular smooth muscle cells promoting excessive contraction.
Endothelin-1, a potent vasoconstrictor released by the endothelium, further exacerbates the constriction of coronary arteries in CAVS. Conversely, impaired release of nitric oxide, a crucial vasodilator, further tilts the balance towards vasoconstriction. Oxidative stress and inflammation also play roles in perpetuating endothelial dysfunction and vascular reactivity.
The episodes of vasospasm in CAVS are often unpredictable and can occur at rest, particularly during periods of heightened sympathetic activity, such as the early morning hours. These spasms result in a temporary reduction of blood flow to the myocardium, leading to angina-like symptoms.
Genetic Predisposition: There is evidence to suggest a genetic component in CAVS. Some individuals may inherit a predisposition that makes them more susceptible to abnormal vascular responses, leading to vasospasms.
Smooth Muscle Abnormalities: Dysfunction in the smooth muscle cells of the coronary arteries can contribute to vasospasm. Abnormal regulation of these cells may result in inappropriate and excessive constriction.
Endothelial Dysfunction: Dysfunction in the endothelial cells can disrupt the balance between vasodilation and vasoconstriction, contributing to vasospasm.
Autonomic Nervous System Imbalance: An imbalance in the autonomic nervous system, particularly between the sympathetic and parasympathetic branches, can influence the regulation of coronary artery tone. This imbalance may contribute to vasospasm.
Vasoactive Substances: Abnormal levels of vasoactive substances, such as endothelin and serotonin, can induce coronary artery constriction. Imbalances in these substances may play a role in the development of vasospasm.
Environmental Triggers: Various external factors can act as triggers for vasospasm. These may include exposure to cold temperatures, emotional stress, certain medications, or substances that affect vascular tone.
Recurring instances of angina are commonly observed in 4% to 19% of patients. Factors such as advanced age and compromised left ventricular function have been recognized as contributors to an unfavorable prognosis in individuals presenting with acute coronary syndrome attributed to coronary artery vasospasm.
Approximately 20% to 30% of individuals reporting chest pain and undergoing assessment for obstructive coronary artery disease through coronary angiography exhibit normal coronary arteries. These patients may or may not exhibit symptoms, and if symptomatic, they might experience typical anginal complaints during episodes of vasospasm.
Pain induced by coronary artery vasospasm can manifest at rest, notably between the night and early morning, often accompanied by reduced exercise tolerance, particularly in the morning hours.
The pain associated with CAVS can be characterized as crushing and substernal, featuring radiation to the jaw or arm. Patients may describe the discomfort as intense, with notable relief observed upon the administration of sublingual nitroglycerin.
It is crucial to recognize that the symptoms may vary, and the presence of vasospasm-induced pain can significantly impact a patient’s quality of life, affecting both daily activities and sleep patterns. These manifestations underscore the importance of a comprehensive understanding of CAVS-related symptoms to facilitate accurate diagnosis and targeted management strategies.
Conducting a comprehensive physical examination is imperative, particularly focusing on the cardiovascular system. The examination should commence by recording vital signs to assess and ensure hemodynamic stability. Subsequently, auscultation of the heart sounds becomes paramount.
Careful attention should be dedicated to evaluating the rhythm, rate, presence of murmurs, and any additional heart sounds like S3 or S4. Moreover, a thorough pulmonary examination is integral, with a specific emphasis on detecting the emergence of crackles.
The presence of crackles may serve as a crucial indicator, potentially suggesting the onset of pulmonary edema. This comprehensive evaluation allows healthcare providers to gather essential information about the cardiovascular status of the patient, facilitating a more accurate diagnosis and informing appropriate management strategies.
The foundation for treating and managing this patient population lies in medical therapy coupled with risk factor modification. Initial treatment involves the administration of nitrates or calcium channel blockers. Nitrates induce the relaxation of vascular muscle by activating guanylate cyclase, leading to an increase in the production of cGMP.
In addressing coronary artery vasospasm (CAVS), it is also essential to employ calcium channel blockers that reduce calcium intake into the vascular smooth muscle. Often, a combination of calcium channel blockers and nitrates may be employed to achieve a more comprehensive vasodilatory effect and better control of vasospastic episodes. This dual approach helps address the underlying vascular smooth muscle dysfunction and provides effective relief from the symptoms associated with CAVS.
While vasodilatation is generally effective in alleviating coronary artery vasospasm, approximately 20% of patients exhibit resistance to drug therapy, even with long-acting medications. Percutaneous balloon angioplasty, in such cases, has not yielded favorable results. Although percutaneous coronary intervention has been explored alongside continued medication use for long-term management, some patients experience recurrent vasospasm in different locations.
Consequently, the consideration of coronary stenting coupled with long-term medical therapy is warranted only for patients exhibiting significant stenosis resulting from CAVS. The utilization of implantable cardioverter-defibrillators (ICDs) in CAVS patients presenting with ventricular tachycardia or ventricular fibrillation remains uncertain. However, there have been reported instances of positive outcomes when implanting ICDs in patients who survive fatal ventricular arrhythmias associated with CAVS.
Calcium Channel blockersÂ
Calcium channel blockers reduce the entry of calcium into vascular smooth muscle cells. By inhibiting calcium influx, these medications prevent the excessive contraction of smooth muscle in the blood vessels, helping to alleviate vasospasm.
Diltiazem is commonly used to prevent and manage coronary artery vasospasm. By reducing calcium entry into smooth muscle cells, it helps prevent excessive vasoconstriction and promotes vasodilation in coronary arteries. Â
NitratesÂ
Nitrates work by releasing nitric oxide, which activates guanylate cyclase, leading to increased production of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels result in vasodilation and relaxation of vascular smooth muscle. Nitroglycerin is often used to provide rapid relief during acute episodes of coronary artery vasospasm. By inducing vasodilation in coronary arteries, it helps alleviate spastic contractions and improve blood flow to the heart.Â
Various alternative therapies have been investigated for the treatment of Coronary Artery Vasospasm (CAVS). These include nicorandil (a nitrate and potassium channel activator), statins, magnesium, fasudil (a rho kinase inhibitor), aspirin, vitamins E and C, iloprost, selective serotonin receptor inhibitors, alpha-receptor blockade, and selective thromboxane A2 synthetase inhibition.
Despite some reported success with these alternatives, their effectiveness remains variable and limited, necessitating further comprehensive studies before they can be universally accepted as primary treatment options, akin to nitrates and calcium channel blockers.
It is crucial to exercise caution with beta-blockers in CAVS management, as they may potentially exacerbate vasospastic angina and are generally advised against in this context. Ongoing research is essential to establish the efficacy and safety profiles of these alternative therapies in the broader spectrum of CAVS treatment.Â
Â
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
